Vonica, R.C.; Butuca, A.; Morgovan, C.; Pumnea, M.; Cipaian, R.C.; Frum, A.; Dobrea, C.M.; Vonica-Tincu, A.L.; Pacnejer, A.-M.; Ghibu, S.;
et al. Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment. Pharmaceuticals 2025, 18, 501.
https://doi.org/10.3390/ph18040501
AMA Style
Vonica RC, Butuca A, Morgovan C, Pumnea M, Cipaian RC, Frum A, Dobrea CM, Vonica-Tincu AL, Pacnejer A-M, Ghibu S,
et al. Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment. Pharmaceuticals. 2025; 18(4):501.
https://doi.org/10.3390/ph18040501
Chicago/Turabian Style
Vonica, Razvan Constantin, Anca Butuca, Claudiu Morgovan, Manuela Pumnea, Remus Calin Cipaian, Adina Frum, Carmen Maximiliana Dobrea, Andreea Loredana Vonica-Tincu, Aliteia-Maria Pacnejer, Steliana Ghibu,
and et al. 2025. "Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment" Pharmaceuticals 18, no. 4: 501.
https://doi.org/10.3390/ph18040501
APA Style
Vonica, R. C., Butuca, A., Morgovan, C., Pumnea, M., Cipaian, R. C., Frum, A., Dobrea, C. M., Vonica-Tincu, A. L., Pacnejer, A.-M., Ghibu, S., Batar, F., & Gligor, F. G.
(2025). Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment. Pharmaceuticals, 18(4), 501.
https://doi.org/10.3390/ph18040501
